Aminoglycosides in septic shock: An overview, with specific consideration given to their nephrotoxic risk

Drug Safety

Volumn 36, Issue 4, 2013, Pages 217-230

  Boyer, Alexandre ^a,b   Gruson, Didier ^a   Bouchet, Stéphane ^a,b   Clouzeau, Benjamin ^a   Hoang Nam, Bui ^a   Vargas, Frédéric ^a   Gilles, Hilbert ^a   Molimard, Mathieu ^a,b   Rogues, Anne Marie ^b   Moore, Nicholas ^a,b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPHOTERICIN B; ANGIOTENSIN ANTAGONIST; CISPLATIN; CLINDAMYCIN; CONTRAST MEDIUM; CYCLOSPORIN; FUROSEMIDE; GENTAMICIN; NETILMICIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIPERACILLIN; TOBRAMYCIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; AREA UNDER THE CURVE; COMORBIDITY; CRITICALLY ILL PATIENT; DEHYDRATION; DISEASE SEVERITY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; NEPHROTOXICITY; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; RISK FACTOR; SEPSIS; SEPTIC SHOCK;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DRUG MONITORING; HUMANS; KIDNEY; RENAL INSUFFICIENCY; RISK FACTORS; SHOCK, SEPTIC;

EID: 84876741206     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0031-0     Document Type: Review

References (176)

1. Vidal L, Gafter-Gvili A, Borok S, et al. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007;60(2):247-57.
2. Drusano GL, Louie A. Optimization of aminoglycoside therapy. Antimicrob Agents Chemother. 2011;55(6):2528-31.
3. Helps A, Deighan C, Gourlay Y, et al. Gentamicin and acute kidney injury requiring renal replacement therapy in the context of a restrictive antibiotic policy. J Antimicrob Chemother. 2011;66(8):1936-8.
4. Leibovici L, Vidal L, Paul M. Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother. 2009;63(2):246-51.
5. Durante-Mangoni E, Grammatikos A, Utili R, et al. Do we still need the aminoglycosides? Int J Antimicrob Agents. 2009;33(3):201-5.
6. Drusano GL, Ambrose PG, Bhavnani SM, et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007;45(6):753-60.
7. Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ. 2004;328(7441):668.
8. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ. 2003;326(7399):1111.
9. Kumar A, Safdar N, Kethireddy S, et al. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Crit Care Med. 2010;38(8):1651-64.
10. Martinez JA, Cobos-Trigueros N, Soriano A, et al. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother. 2010;54(9):3590-6.
11. Bhat S, Fujitani S, Potoski BA, et al. Pseudomonas aeruginosa infections in the intensive care unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved? Int J Antimicrob Agents. 2007;30(5):458-62.
12. Beardsley JR, Williamson JC, Johnson JW, et al. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest. 2006;130(3):787-93.
13. Marcus R, Paul M, Elphick H, et al. Clinical implications of beta-lactam-aminoglycoside synergism: systematic review of randomised trials. Int J Antimicrob Agents. 2011;37(6):491-503.
14. Prins JM, Weverling GJ, de Blok K, et al. Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother. 1996;40(11):2494-9.
15. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650-5.
16. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 1995;39(6):605-9.
17. Zahar JR, Rioux C, Girou E, et al. Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team. J Antimicrob Chemother. 2006;58(3):651-6.
18. Taber SS, Mueller BA. Drug-associated renal dysfunction. Crit Care Clin. 2006;22(2):357-74, viii.
19. Brivet FG, Kleinknecht DJ, Loirat P, et al. Acute renal failure in intensive care units - causes, outcome, and prognostic factors of hospital mortality: a prospective, multicenter study. French Study Group on Acute Renal Failure. Crit Care Med. 1996;24(2):192-8.
20. Zager RA, Prior RB. Gentamicin and gram-negative bacteremia: a synergism for the development of experimental nephrotoxic acute renal failure. J Clin Invest. 1986;78(1):196-204.
21. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43(5):1003-12.
22. Lopez-Novoa JM, Quiros Y, Vicente L, et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011;79(1):33-45.
23. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43(7):1549-55.
24. Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009;48(6):713-21.
25. Bartal C, Danon A, Schlaeffer F, et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med. 2003;114(3):194-8.
26. Schentag JJ, Plaut ME, Cerra FB. Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients. Antimicrob Agents Chemother. 1981;19(5):859-66.
27. Schentag JJ, Wels PB, Reitberg DP, et al. A randomized clinical trial of moxalactam alone versus tobramycin plus clindamycin in abdominal sepsis. Ann Surg. 1983;198(1):35-41.
28. Kirkpatrick CM, Duffull SB, Begg EJ, et al. The use of a change in gentamicin clearance as an early predictor of gentamicin-induced nephrotoxicity. Ther Drug Monit. 2003;25(5):623-30.
29. Saunders MA, Mitchell JA, Seldon PM, et al. Release of granulocyte-macrophage colony stimulating factor by human cultured airway smooth muscle cells: suppression by dexamethasone. Br J Pharmacol. 1997;120(4):545-6.
30. Tulkens PM. Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Chemother. 1991;27(Suppl. C):49-61.
31. Mondorf AW, Zegelman M, Klose J, et al. Comparative studies on the action of aminoglycosides and cephalosporins on the proximal tubule of the human kidney. J Antimicrob Chemother. 1978;4(Suppl. A):53-7.
32. Barclay ML, Begg EJ, Chambers ST, et al. Improved efficacy with nonsimultaneous administration of first doses of gentamicin and ceftazidime in vitro. Antimicrob Agents Chemother. 1995;39(1):132-6.
33. Nix DE, Thomas JK, Symonds WT, et al. Assessment of the enzymuria resulting from gentamicin alone and combinations of gentamicin with various beta-lactam antibiotics. Ann Pharmacother. 1997;31(6):696-703.
34. Olsen KM, Rudis MI, Rebuck JA, et al. Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med. 2004;32(8):1678-82.
35. Prins JM, Weverling GJ, van Ketel RJ, et al. Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients. Clin Pharmacol Ther. 1997;62(1):106-11.
36. Rougier F, Claude D, Maurin M, et al. Aminoglycoside nephrotoxicity: modeling, simulation, and control. Antimicrob Agents Chemother. 2003;47(3):1010-6.
37. Sawyers CL, Moore RD, Lerner SA, et al. A model for predicting nephrotoxicity in patients treated with aminoglycosides. J Infect Dis. 1986;153(6):1062-8.
38. Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med. 1984;100(3):352-7.
39. Lam YW, Arana CJ, Shikuma LR, et al. The clinical utility of a published nomogram to predict aminoglycoside nephrotoxicity. JAMA. 1986;255(5):639-42.
40. Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999;43(3):623-9.
41. De Broe ME, Verbist L, Verpooten GA. Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man. J Antimicrob Chemother. 1991;27(Suppl. C):41-7.
42. Verpooten GA, Giuliano RA, Verbist L, et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther. 1989;45(1):22-7.
43. Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Crit Care Med. 2008;36(4 Suppl.):S216-23.
44. Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1993;341(8841):335-9.
45. Hitt CM, Klepser ME, Nightingale CH, et al. Pharmacoeconomic impact of once-daily aminoglycoside administration. Pharmacotherapy. 1997;17(4):810-4.
46. Barza M, Ioannidis JP, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996;312(7027):338-45.
47. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24(5):796-809.
48. Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24(5):786-95.
49. Mavros MN, Polyzos KA, Rafailidis PI, et al. Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66(2):251-9.
50. Buchholtz K, Larsen CT, Hassager C, et al. Severity of gentamicin's nephrotoxic effect on patients with infective endocarditis: a prospective observational cohort study of 373 patients. Clin Infect Dis. 2009;48(1):65-71.
51. Matzke GR, Frye RF. Drug administration in patients with renal insufficiency: minimising renal and extrarenal toxicity. Drug Saf. 1997;16(3):205-31.
52. Smyth A, Lewis S, Bertenshaw C, et al. Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax. 2008;63(6):532-5.
53. Rougier F, Ducher M, Maurin M, et al. Aminoglycoside dosages and nephrotoxicity: quantitative relationships. Clin Pharmacokinet. 2003;42(5):493-500.
54. Bertino JS Jr, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 1993;167(1):173-9.
55. Leehey DJ, Braun BI, Tholl DA, et al. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy. J Am Soc Nephrol. 1993;4(1):81-90.
56. Tod M, Minozzi C, Beaucaire G, et al. Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study. J Antimicrob Chemother. 1999;44(1):99-108.
57. Dang L, Duffull S. Development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis. J Clin Pharmacol. 2006;46(6):662-73.
58. Tofte RW, Canafax DM, Simmons RL, et al. Aminoglycoside dosing in renal transplant patients: comparison of nomogram and individualized pharmacokinetic methods in patients with shifting renal function. Ann Surg. 1982;195(3):287-93.
59. Finley RS, Fortner CL, deJongh CA, et al. Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients. Antimicrob Agents Chemother. 1982;22(2):193-7.
60. Arroyo JC, Milligan WL, Davis J, et al. Impact of aminoglycoside serum assays on clinical decisions and renal toxicity. South Med J. 1986;79(3):272-6.
61. Burton ME, Ash CL, Hill DP Jr, et al. A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration. Clin Pharmacol Ther. 1991;49(6):685-94.
62. Destache CJ, Meyer SK, Rowley KM. Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis. Therap Drug Monit. 1990;12(5):427-33.
63. Noone P, Beale DF, Pollock SS, et al. Monitoring aminoglycoside use in patients with severely impaired renal function. BMJ. 1978;2(6135):470-3.
64. Greenwood BC, Szumita PM, Lowry CM. Pharmacist-driven aminoglycoside quality improvement program. J Chemother. 2009;21(1):42-5.
65. Bond CA, Raehl CL. Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy. Am J Health Syst Pharm. 2005;62(15):1596-605.
66. Kimelblatt BJ, Bradbury K, Chodoff L, et al. Cost-benefit analysis of an aminoglycoside monitoring service. Am J Hosp Pharm. 1986;43(5):1205-9.
67. MacLaren R, Bond CA, Martin SJ, et al. Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections. Crit Care Med. 2008;36(12):3184-9.
68. Nagai J, Takano M. Molecular-targeted approaches to reduce renal accumulation of nephrotoxic drugs. Expert Opin Drug Metab Toxicol. 2010;6(9):1125-38.
69. Balakumar P, Rohilla A, Thangathirupathi A. Gentamicin-induced nephrotoxicity: do we have a promising therapeutic approach to blunt it? Pharmacol Res. 2010;62(3):179-86.
70. Slaughter RL, Cappelletty DM. Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring. Pharmacoeconomics. 1998;14(4):385-94.
71. French MA, Cerra FB, Plaut ME, et al. Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients. Antimicrob Agents Chemother. 1981;19(1):147-52.
72. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204-12.
73. Selby NM, Shaw S, Woodier N, et al. Gentamicin-associated acute kidney injury. QJM. 2009;102(12):873-80.
74. Shrimpton SB, Milmoe M, Wilson AP, et al. Audit of prescription and assay of aminoglycosides in a UK teaching hospital. J Antimicrob Chemother. 1993;31(4):599-606.
75. Li SC, Ioannides-Demos LL, Spicer WJ, et al. Prospective audit of aminoglycoside usage in a general hospital with assessments of clinical processes and adverse clinical outcomes. Med J Aust. 1989;151(4):224-32.
76. Hajkowicz KM, Post JJ. Does aminoglycoside therapy cause significant acute kidney injury in febrile neutropenia? Int J Antimicrob Agents. 2011;37(1):78-81.
77. Fayed DF, Dahmash NS, al-Zeer AH, et al. Efficacy and safety of once-daily amikacin in combination with ceftazidime in critically ill adults with severe gram-negative infections. J Chemother. 1996;8(6):457-64.
78. Buijk SE, Mouton JW, Gyssens IC, et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med. 2002;28(7):936-42.
79. Boucher BA, Coffey BC, Kuhl DA, et al. Algorithm for assessing renal dysfunction risk in critically ill trauma patients receiving aminoglycosides. Am J Surg. 1990;160(5):473-80.
80. Kubota K, Suganuma T, Sasaki T, et al. An approach to forecast aminoglycoside-related nephrotoxicity from routinely collected clinical data. Ther Drug Monit. 1988;10(4):410-20.
81. Cuhaci B. More data on epidemiology and outcome of acute kidney injury with AKIN criteria: benefits of standardized definitions, AKIN and RIFLE classifications. Crit Care Med. 2009;37(9):2659-61.
82. Cartin-Ceba R, Haugen EN, Iscimen R, et al. Evaluation of "loss" and "end stage renal disease" after acute kidney injury defined by the Risk, Injury, Failure, Loss and ESRD classification in critically ill patients. Intensive Care Med. 2009;35(12):2087-95.
83. Marik PE, Lipman J, Kobilski S, et al. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother. 1991;28(5):753-64.
84. Czock D, Giehl M, Keller F. A concept for pharmacokinetic-pharmacodynamic dosage adjustment in renal impairment: the case of aminoglycosides. Clin Pharmacokinet. 2000;38(4):367-75.
85. Laczika K, Staudinger T, Hollenstein U, et al. Renal tolerability of four different once-daily dose regimen of netilmicin in critical care patients. Wien Klin Wochenschr. 1997;109(21):840-4.
86. Fukuoka N, Aibiki M. Recommended dose of arbekacin, an aminoglycoside against methicillin-resistant Staphylococcus aureus, does not achieve desired serum concentration in critically ill patients with lowered creatinine clearance. J Clin Pharm Ther. 2008;33(5):521-7.
87. Charbonneau P, Parienti JJ, Thibon P, et al. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis. 2006;42(6):778-84.
88. Gruson D, Hilbert G, Vargas F, et al. Rotation and restricted use of antibiotics in a medical intensive care unit: impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria. Am J Respir Crit Care Med. 2000;162(3 Pt 1):837-43.
89. Paterson DL, Robson JM, Wagener MM. Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Gen Intern Med. 1998;13(11):735-9.
90. Oliveira JF, Silva CA, Barbieri CD, et al. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother. 2009;53(7):2887-91.
91. Radigan EA, Gilchrist NA, Miller MA. Management of aminoglycosides in the intensive care unit. J Intensive Care Med. 2010;25(6):327-42.
92. Joannidis M, Metnitz B, Bauer P, et al. Acute kidney injury in critically ill patients classified by AKIN versus RIFLE using the SAPS 3 database. Intensive Care Med. 2009;35(10):1692-702.
93. Zager RA. Endotoxemia, renal hypoperfusion, and fever: interactive risk factors for aminoglycoside and sepsis-associated acute renal failure. Am J Kid Dis. 1992;20(3):223-30.
94. Zager RA. Gentamicin nephrotoxicity in the setting of acute renal hypoperfusion. Am J Physiol. 1988;254(4 Pt 2):F574-81.
95. Lipcsey M, Carlsson M, Larsson A, et al. Effect of a single dose of tobramycin on systemic inflammatory response-induced acute kidney injury in a 6-hour porcine model. Crit Care Med. 2009;37(10):2782-90.
96. Peng ZY, Wang HZ, Srisawat N, et al. Bactericidal antibiotics temporarily increase inflammation and worsen acute kidney injury in experimental sepsis. Crit Care Med. 2012;40(2):538-43.
97. Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48(12):1724-8.
98. Goetz DR, Pancorbo S, Hoag S, et al. Prediction of serum gentamicin concentrations in patients undergoing hemodialysis. Am J Hosp Pharm. 1980;37(8):1077-83.
99. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother. 1993;32(2):325-34.
100. Mehta RL. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002;288(20):2547-53.
101. Lameire NH. Contrast-induced nephropathy: prevention and risk reduction. Nephrol Dial Transplant. 2006;21(6):i11-23.
102. Rea RS, Capitano B, Bies R, et al. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit. 2008;30(6):674-81.
103. Tod MM, Padoin C, Petitjean O. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? Clin Pharmacokinet. 2001;40(11):803-14.
104. Tang GJ, Tang JJ, Lin BS, et al. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol Scand. 1999;43(7):726-30.
105. Lugo G, Castaneda-Hernandez G. Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis. Ther Drug Monit. 1997;19(3):271-6.
106. Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care. 1993;21(2):172-3.
107. Botha FJ, van der Bijl P, Seifart HI, et al. Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. Intensive Care Med. 1996;22(5):443-6.
108. Rea RS, Capitano B. Optimizing use of aminoglycosides in the critically ill. Semin Respir Crit Care Med. 2007;28(6):596-603.
109. Lugo G, Castaneda-Hernandez G. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med. 1997;25(5):806-11.
110. Schentag JJ, Jusko WJ, Vance JW, et al. Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm. 1977;5(6):559-77.
111. Kirkpatrick CM, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol. 1999;47(6):637-43.
112. Oparaoji EC, Siram S, Shoheiber O, et al. Appropriateness of a 4 mg/kg gentamicin or tobramycin loading dose in post-operative septic shock patients. J Clin Pharm Ther. 1998;23(3):185-90.
113. Toschlog EA, Blount KP, Rotondo MF, et al. Clinical predictors of subtherapeutic aminoglycoside levels in trauma patients undergoing once-daily dosing. J Trauma. 2003;55(2):255-60 (discussion 60-2).
114. Barletta JF, Johnson SB, Nix DE, et al. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. J Trauma. 2000;49(5):869-72.
115. Dasta JF, Armstrong DK. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med. 1988;16(4):327-30.
116. Friggeri A MF, Marry L, Dupont H. Etude Pharmacocinétique de l'amikacine: intérêt des facteurs cliniques et biologiques. Reanimation. 2009;18(Suppl.):S3.
117. Bacopoulou F, Markantonis SL, Pavlou E, et al. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes. J Crit Care. 2003;18(2):107-13.
118. Triginer C, Izquierdo I, Fernandez R, et al. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med. 1990;16(5):303-6.
119. Tod M, Lortholary O, Seytre D, et al. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults. Antimicrob Agents Chemother. 1998;42(4):849-56.
120. Kaye D, Levison ME, Labovitz ED. The unpredictability of serum concentrations of gentamicin: pharmacokinetics of gentamicin in patients with normal and abnormal renal function. J Infect Diss. 1974;130(2):150-4.
121. Hickling K, Begg E, Moore ML. A prospective randomised trial comparing individualised pharmacokinetic dosage prediction for aminoglycosides with prediction based on estimated creatinine clearance in critically ill patients. Intensive Care Med. 1989;15(4):233-7.
122. Charhon N, Neely MN, Bourguignon L, et al. Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients. Antimicrob Agents Chemother. 2012;56(4):1862-9.
123. Pai MP, Nafziger AN, Bertino JS Jr. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother. 2011;55(9):4006-11.
124. Tholl DA, Shikuma LR, Miller TQ, et al. Physiologic response of stress and aminoglycoside clearance in critically ill patients. Critical Care Med. 1993;21(2):248-51.
125. Beaucaire G. Does once-daily dosing prevent nephrotoxicity in all aminoglycosides equally? Clin Microbiol Infect. 2000;6(7):357-62.
126. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother. 1996;37(4):645-63.
127. Chuck SK, Raber SR, Rodvold KA, et al. National survey of extended-interval aminoglycoside dosing. Clin Infect Dis. 2000;30(3):433-9.
128. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155(1):93-9.
129. Potel G, Caillon J, Jacqueline C, Navas D, Kergueris MF, Batard E. Antibiotic dosages in intensive care unit: when and how should we ask for and perform tests? Reanimation. 2006;15:187-92.
130. McKenzie C. Antibiotic dosing in critical illness. J Antimicrob Chemother. 2011;66(Suppl. 2):ii25-31.
131. Mise au point sur le bon usage des aminosides administrés par voie injectable: gentamicine, tobramycine, nétilmicine, amikacine. Available from URL: http://ansm.sante.fr/var/ansm-site/storage/original/application/ f64613ed667c09bcb015026fa39e70a2.pdf. Accessed 2013 Feb 2.
132. Pieracci FM, Barie PS, Pomp A. Critical care of the bariatric patient. Crit Care Med. 2006;34(6):1796-804.
133. Sowinski KM, Magner SJ, Lucksiri A, et al. Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol. 2008;3(2):355-61.
134. Teigen MM, Duffull S, Dang L, et al. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol. 2006;46(11):1259-67.
135. Aronoff GR, Berns JS, Brier ME, et al. Drug prescribing in renal failure: dosing guidelines for adults and children. Philadelphia: ACP Press; 2007.
136. Keller F, Wagner K, Borner K, et al. Aminoglycoside dosage in hemodialysis patients. J Clin Pharmacol. 1986;26(8):690-5.
137. Ash SR, Millikan MD. Optimizing tobramycin therapy in a hemodialysis patient. Int J Artif Organs. 1982;5(4):279-80.
138. Matsuo H, Hayashi J, Ono K, et al. Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality. Antimicrob Agents Chemother. 1997;41(12):2597-601.
139. Veinstein A, Dupuis A, Pinsard M, Venisse N, Robert R. Optimisation de la pharmacodynamie de la gentamycine chez le patient de réanimation en insuffisance réanle aigüe hémodialysé. Reanimation. 2010;19(Suppl. 1):S63-4.
140. Ernest D, Cutler DJ. Gentamicin clearance during continuous arteriovenous hemodiafiltration. Critical Care Med. 1992;20(5):586-9.
141. Zarowitz BJ, Anandan JV, Dumler F, et al. Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients. J Clin Pharmacol. 1986;26(8):686-9.
142. Armendariz E, Chelluri L, Ptachcinski R. Pharmacokinetics of amikacin during continuous veno-venous hemofiltration. Crit Care Med. 1990;18(6):675-6.
143. Roberts JA, Field J, Visser A, et al. Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. Antimicrob Agents Chemother. 2010;54(9):3635-40.
144. Golper TA. Update on drug sieving coefficients and dosing adjustments during continuous renal replacement therapies. Contrib Nephrol. 2001;132:349-53.
145. Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41(8):1159-66.
146. Yamamoto T, Yasuno N, Katada S, et al. Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration. Antimicrob Agents Chemother. 2011;55(12):5804-12.
147. Bogard KN, Peterson NT, Plumb TJ, et al. Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients. Crit Care Med. 2011;39(3):560-70.
148. Akers KS, Cota JM, Frei CR, et al. Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2011;55(10):4639-42.
149. Chambers HF. Aminoglycosides. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2006.
150. Flint LM, Gott J, Short L, et al. Serum level monitoring of aminoglycoside antibiotics. Limitations in intensive care unit-related bacterial pneumonia. Arch Surg. 1985;120(1):99-103.
151. Franson TR, Quebbeman EJ, Whipple J, et al. Prospective comparison of traditional and pharmacokinetic aminoglycoside dosing methods. Critical Care Med. 1988;16(9):840-3.
152. Lesar TS, Rotschafer JC, Strand LM, et al. Gentamicin dosing errors with four commonly used nomograms. JAMA. 1982;248(10):1190-3.
153. Platt DR, Matthews SJ, Sevka MJ, et al. Comparison of four methods of predicting serum gentamicin concentrations in adult patients with impaired renal function. Clin Pharm. 1982;1(4):361-5.
154. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1976;4(2):183-95.
155. Wallace AW, Jones M, Bertino JS Jr. Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy. 2002;22(9):1077-83.
156. Reed RL 2nd, Wu AH, Miller-Crotchett P, et al. Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients. J Trauma. 1989;29(11):1462-8 (discussion 8-70).
157. Bressolle F, Gouby A, Martinez JM, et al. Population pharmacokinetics of amikacin in critically ill patients. Antimicrob Agents Chemother. 1996;40(7):1682-9.
158. Denaro CP, Ravenscroft PJ. Usefulness of estimating individual pharmacokinetic data for aminoglycoside therapy in seriously ill patients. Aust N Z J Med. 1987;17(5):526-32.
159. Lacarelle B, Granthil C, Manelli JC, et al. Evaluation of a Bayesian method of amikacin dosing in intensive care unit patients with normal or impaired renal function. Ther Drug Monit. 1987;9(2):154-60.
160. Destache CJ, Meyer SK, Bittner MJ, et al. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Ther Drug Monit. 1990;12(5):419-26.
161. Feldman L, Efrati S, Eviatar E, et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int. 2007;72(3):359-63.
162. Zaske DE, Bootman JL, Solem LB, et al. Increased burn patient survival with individualized dosages of gentamicin. Surgery. 1982;91(2):142-9.
163. Mithani H, Brown G. The economic impact of once-daily versus conventional administration of gentamicin and tobramycin. Pharmacoeconomics. 1996;10(5):494-503.
164. Beaucaire G. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia. J Chemother. 1995;7(Suppl. 2):165-73.
165. Eisenberg JM, Koffer H, Glick HA, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med. 1987;107(6):900-9.
166. Fischer MO, Parienti JJ, Daurel C, et al. An information campaign on aminoglycosides use during septic shock failed to improve the quality of care. Ann Fr Anesth Reanim. 2012;31(1):e1-5.
167. Boyer A GE, Grenouillet-Delacre M, Bouchet S, Thiebault R, Picard W, Clouzeau B, Hilbert G, Molimard M, Rogues AM, Gruson D. Le risque néphrotoxique de la precsritpion d'aminoglycosides en réanimation: étude observationnelle prospective. Reanimation. 2010;19(Suppl.1):S63.
168. Streetman DS, Nafziger AN, Destache CJ, et al. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy. 2001;21(4):443-51.
169. Lawson DH, Tilstone WJ, Gray JM, et al. Effect of furosemide on the pharmacokinetics of gentamicin in patients. J Clin Pharmacol. 1982;22(5-6):254-8.
170. Smith CR, Lietman PS. Effect of furosemide on aminoglycoside-induced nephrotoxicity and auditory toxicity in humans. Antimicrob Agents Chemother. 1983;23(1):133-7.
171. Sweileh WM. Gender differences in aminoglycoside induced nephrotoxicity: a prospective, hospital-based study. Curr Clin Pharmacol. 2009;4(3):229-32.
172. Baciewicz AM, Sokos DR, Cowan RI. Aminoglycoside-associated nephrotoxicity in the elderly. Annals Pharmacother. 2003;37(2):182-6.
173. Hampel H, Bynum GD, Zamora E, et al. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol. 2001;96(7):2206-10.
174. Cortes J, Gamba G, Contreras A, et al. Amikacin nephrotoxicity in patients with chronic liver disease. Rev Invest Clin. 1990;42(2):93-8.
175. Contreras AM, Ramirez M, Cueva L, et al. Low serum albumin and the increased risk of amikacin nephrotoxicity. Rev Invest Clin. 1994;46(1):37-43.
176. Dictionnaire Vidal. Available from URL: http://www.vidal.fr/. Accessed 2013 Feb 21.